Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement

Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma

(2013) J. Ying et al.   ANNALS OF ONCOLOGY

Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies

(2013) Yan Xiong et al.   Diagnostic Pathology

High MET gene copy number predicted poor prognosis in primary intestinal diffuse large B-cell lymphoma

(2013) Wan-Ting Huang et al.   Diagnostic Pathology

Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients

(2013) Pablo Martinez et al.   PLoS One

ALK-Rearranged Lung Cancer in Chinese: A Comprehensive Assessment of Clinicopathology, IHC, FISH and RT-PCR

(2013) Yuan Li et al.   PLoS One

Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement,ALKsignal copy number, and response to crizotinib therapy inALKfluorescence in situ hybridization-positive nonsmall cell lung cancer

(2012) D. Ross Camidge et al.   CANCER

A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient with IHC-Positive and FISH-Negative ALK

(2012) Jong-Mu Sun et al.   Journal of Thoracic Oncology

Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene

(2012) Takayuki Fukui et al.   LUNG CANCER

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

(2011) J. Jean Cui et al.   JOURNAL OF MEDICINAL CHEMISTRY

A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry

(2010) M. Mino-Kenudson et al.   CLINICAL CANCER RESEARCH

Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma

(2010) R. Jokoji et al.   JOURNAL OF CLINICAL PATHOLOGY

Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene

(2009) Tsuyoshi Takahashi et al.   ANNALS OF SURGICAL ONCOLOGY

TheEML4-ALKfusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-typeEGFRandKRAS

(2009) Daisy Wing-Sze Wong et al.   CANCER

Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population

(2009) S. J. Rodig et al.   CLINICAL CANCER RESEARCH

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

(2009) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology and young onset

(2009) Kentaro Inamura et al.   MODERN PATHOLOGY

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A mouse model for EML4-ALK-positive lung cancer

(2008) M. Soda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA